New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and MaRS Innovation, a non-profit organization supporting the commercialization of research breakthroughs from Toronto’s leading academic institutions, today announced the launch of Bright Angel Therapeutics. The new Toronto-based company is focused on the development of novel therapeutics for treatment of drug-resistant and life-threatening fungal infections. Bright Angel’s first program is based on foundational research from ...
Click on link to read an article by Drs. Rafi Hofstein and Werner Lanthaler published in December 2017 in the online publication Global University Venturing: http://bit.ly/2Ba9vH2
Toronto, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics (Fibrocor) announced today that Mark Steedman has been appointed as its first president and CEO, and will serve as a member of Fibrocor’s board of directors.
Mr. Steedman is the co-founder of Interface Biologics where he most recently served as VP, Business Development. He was responsible for all start-up operations including financing and business development up to Series A totaling $13M, and was instrumental in early transactions with large multinational corporations, which ultimately led ...
TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE).
Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target.
Nacellins are a type of peptide macrocycle that can often exhibit ...
Toronto, Sept. 14, 2017 (GLOBE NEWSWIRE) -- MaRS Innovation (“MI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the launch of “LAB150”. This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.
A crucial lack of the funding, specialized infrastructure and drug development expertise necessary to translate disease-related biological pathways into focused drug ...
Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec, has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province,patients and sleep physicians will have the option to diagnose sleep apnea in the home.
Invented at the Toronto Rehabilitation Institute by Dr. Hisham Alshaer, BresoDx® is the world’s first cordless, single-user, home sleep test used to diagnose sleep apnea. BresoDx® aims ...
TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed in December 2016 during Premier Wynne's mission to the Republic of Korea.
Together with Minister Moridi, Ontario Minister of Research, Innovation and Science, Rafi Hofstein, CEO of MI, is in Seoul to further the joint research initiatives first envisaged last year. Five outstanding Ontario scientists from some of MI's Member institutions are ...
TORONTO (February 13, 2017): QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led by DSM Venturing, with matching investment participation from existing investors, MaRS innovation and KAUST Innovation Fund.
The development of this technology is also supported by project funding that was announced in March 2016 from Sustainable Development Technology Canada (SDTC) through a C$2.5M grant, and through the generous support of the Ontario Research ...
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers.
Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York UniversityProfessor Michael Riddell, published first-of-its-kind guidelines to help people with type 1 diabetes exercise safely.
The report, “Exercise management in type 1 diabetes: a consensus statement,” published this week in The Lancet Diabetes & Endocrinology, offers guidelines on ...
Toronto, Canada and Hamburg, Germany, 17 January 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP (“Fibrocor”), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from MaRS Innovation. Evotec will provide all drug discovery activities and will also receive an equity stake.
Fibrocor takes a new approach to understanding and ...